Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink
Comparison of disease-free survival (A) and overall survival (B) among... | Download Scientific Diagram
Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink
Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis - The Lancet Oncology
Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom?
Disease-free survival landmark analysis: a potential critical endpoint in triple-negative breast cancer | Experimental Hematology & Oncology | Full Text
Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram
Disease Free Survival - an overview | ScienceDirect Topics
![PDF] Clinical endpoints in oncology - a primer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f33163534f9a85acc25579932597eab0cf9e71ff/7-Figure1-1.png "PDF] Clinical endpoints in oncology - a primer. | Semantic Scholar")
PDF] Clinical endpoints in oncology - a primer. | Semantic Scholar
The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The
Frontiers | Disease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder:
Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom?
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
Overall survival (a) and disease-free survival (b) among the entire... | Download Scientific Diagram
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
The Disease-Free Interval Between Resection of Primary Colorectal Malignancy and the Detection of Hepatic Metastases Predicts Disease Recurrence But Not Overall Survival | SpringerLink
JPM | Free Full-Text | Impact of Tumor LINE-1 Methylation Level and Neoadjuvant Treatment and Its Association with Colorectal Cancer Survival
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma | Haematologica
Comparison Overall survival and Disease free survival graph between two... | Download Scientific Diagram
